Dedicated clinical-stage and early commercial gene-editing companies like CRISPR Therapeutics are not yet consistently profitable on a net income basis. While they generate substantial and rapidly growing top-line collaboration and product revenues from treatments like Casgevy, massive ongoing capital investments into research, development, clinical trials, and manufacturing infrastructure mean they continue to report net operating losses as they scale.